Topic: renal cell carcinoma
In a "Groundhog Day" scenario, the FDA has once more slapped down Aveo Oncology’s attempt to get its ill-fated cancer drug on the U.S. market.
The phase 3 program was one of five projects removed from AstraZeneca’s pipeline in conjunction with its second-quarter results.
Immunicum’s dendritic cell vaccine ilixadencel has failed to better the 18-month survival rate achieved by Pfizer’s Sutent in renal cell carcinoma.
The deal will give Merck control of an experimental oral HIF-2α inhibitor that may challenge Keytruda for the metastatic renal cell carcinoma market.
The series B round comes shortly after Actuate dosed the first patient in a phase 1/2 trial of glycogen synthase kinase‐3 beta 9-ING-41.
The agency advised Aveo against filing a NDA after data failed to address the concerns that led it to reject the drug in renal cell carcinoma in 2013.
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
The spectacular rehabilitation of Aveo's cancer drug tivozanib continues with E.U. approval as a treatment for advanced kidney cancer.
The deal sees CRUK take a stake in the biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with solid tumors.
Aveo Pharmaceuticals’ troubled tivozanib is on the cusp of winning approval in Europe, sending its stock on a tear.